Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Classical hematology 2Tumor-Agnostic 1

Conditions

Neoplasms 2Non-hematological Malignancies 1Anemia, Iron-Deficiency 1Anemia 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × INDUSTRY × iron isomaltoside 1000 × Clear all
NCT04318405 2023-07-19

Real-CHOICE

Pierre Fabre Pharma AG

Completed
327 enrolled
Classical hematology

Anemia, Iron-Deficiency

NCT01145638 2015-12-03

A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

Pharmacosmos A/S

Phase 3 Completed
350 enrolled 9 charts
Tumor-Agnostic

Neoplasms

NCT01213979 2013-06-27

PK-CIA-04

Pharmacosmos A/S

Phase 1 Completed
16 enrolled

Non-hematological Malignancies

NCT01280240 2013-06-04

PK-CIA-06

Pharmacosmos A/S

Phase 1 Completed
11 enrolled
Classical hematology

Anemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡